“This Isn’t a Life”: An Analysis of EQ-5D in a Cohort of Individuals with Long COVID Symptoms

Author(s)

McCullough A1, Lorgelly P2, Exeter D3, Crossan J3
1University of Auckland, Grafton, AUK, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Auckland, Grafton, Auckland, New Zealand

OBJECTIVES: Long COVID is expected to be the most significant and enduring impact of the COVID-19 pandemic. This study provides evidence of the impact of long COVID symptoms on EQ-5D-5L, change in this impact and explores any mediators of the impact.

METHODS: Mātauranga Raranga | Long COVID Registry Aotearoa collects data on individuals who self-report symptoms of long COVID. Health-related quality-of-life (HRQoL) is collected using the EQ-5D-5L, using recall for pre-COVID HRQoL and today (with long COVID symptoms), with monthly follow-up. The registry is underpinned by a Tiriti o Waitangi Framework and partnership model of practice which seeks to avoid deficit framing. Separate analyses of Māori and non-Māori explore the mean EQ-5D-5L values and profiles. Quality adjusted life years (QALYs) are estimated using the date of the index infection and data collected at various follow-up points. Regression analyses are used to understand the determinants of EQ-5D-5L and changes over time.

RESULTS: Analyses of collected data up to 30 September 2023 have formed the bases of an interim report (8.3% Māori; 91.7% non-Māori). Pre-COVID (baseline) and today EQ-5D-5L had a mean value of 0.853 (0.892) and 0.484 (0.533) respectively for Māori (non-Māori), with the difference in EQ-5D-5L (and EQ-VAS) being significant. The average time with symptoms of long COVID for Māori (non-Māori) participants is 367 days (336 days). Estimated QALYs lost due to long COVID is 0.41 (0.30) QALYs for Māori (non-Māori). Further analyses are ongoing, including with a larger and more representative sample, as the registry continues to recruit individuals with long COVID symptoms.

CONCLUSIONS: This study shows that the impact of long COVID symptoms on HRQoL is similar to that of individuals with MS and cancer. Further research is warranted to understand the determinants of this burden and whether time or treatment mediates the impact.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

EE422

Topic

Economic Evaluation, Patient-Centered Research

Topic Subcategory

Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×